Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials

Abstract Background Migraine is one of the most common neurological diseases around world and calcitonin gene-related peptide (CGRP) plays an important role in its pathophysiology. Therefore, present study, we evaluated efficacy monoclonal antibodies blocking CGRP ligand or receptor episodic chronic migraine. Objective The objective our study implementing a meta-analysis to systematically evaluate safety eptinezumab for treatment migraine compared with placebo. Method We searched Medline, Embase, Cochrane Library Clinicaltrials.gov randomized controlled trials (RCTs) which were performed versus placebo up September 2020. data was assessed by Review Manager 5.3 software. risk ratio (RR) standard mean difference (SMD) analyzed using dichotomous outcomes continuous respectively random effect model. Result collected 2739 patients from 4 RCTs: primary endpoint change baseline week 12 monthly days (MMDs). found that (30 mg, 100 300 mg) led significant reduction MMDs ( P = 0.0001, < 0.00001, 0.00001) during weeks placebo, especially mg. For safety, concluded emergent adverse events (TEAEs) RCTs. This indicated no evident statistical between Conclusions In safe has migraine, dose